Pancreatic cancer specialist expects to open trials on promising pill
Oncologists in Toronto are preparing to launch clinical trials for a new pancreatic cancer pill called daraxonrasib. The drug has shown potential to double survival times in recent U.S.-led studies.
Why it matters
Pancreatic cancer is notoriously difficult to treat, and a breakthrough in survival rates represents a major medical advancement.
TORONTO — Oncologists say they’re working to quickly get Canadian patients with pancreatic cancer into clinical trials for a new pill that could double their survival time.
Objective reporting on medical research and clinical trial developments.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in